OTLK stock news

OTLK stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-09 12:30:00 UTC#438275newconfirmedpress release

Outlook Therapeutics (OTLK) appoints Greg DiPasquale as Chief Commercial Officer to lead LYTENAVA launch

globenewswireimportance 0.30trust 1.00Outlook Therapeutics, Inc. +0.30Greg DiPasquale +0.30LYTENAVA +0.30+2 entities

2026-09-11 10:14:00 UTC#297826newconfirmednews

Ascendiant Capital maintains Buy rating on Outlook Therapeutics (OTLK)

dow_jonesimportance 0.30trust 0.60Outlook Therapeutics, Inc. +0.20Ascendiant Capital Markets, LLC +0.20

2026-09-10 13:10:00 UTC#292350newconfirmednews

Outlook Therapeutics CEO Bob Jahr targets over $500M in annual US sales for LYTENAVA by 2030

globenewswireimportance 0.40trust 0.90Outlook Therapeutics, Inc. +0.60Bob Jahr 0LYTENAVA +0.60+1 entities

2026-08-18 21:41:01 UTC#191917newconfirmeddata release

Outlook Therapeutics Q2 2026 revenue $8.7K vs $1.51M YoY, EPS $(0.15) vs $(0.55)

tradingviewimportance 0.40trust 0.80Outlook Therapeutics, Inc. -0.30LYTENAVA +0.20

2026-08-14 17:08:02 UTC#179337newconfirmednews

Outlook Therapeutics forecasts $50M-$75M first-year net revenue for LYTENAVA, targeting $500M+ peak by 2030

seeking alphaimportance 0.40trust 0.70Outlook Therapeutics, Inc. +0.40LYTENAVA +0.40

2026-08-14 13:31:11 UTC#178250duplicateconfirmednews

Outlook Therapeutics reports Q3 adjusted loss of $0.09/share, revenue of $9,000

reutersimportance 0.30trust 0.90Outlook Therapeutics, Inc. -0.40

2026-08-14 13:29:20 UTC#178267updateconfirmednews

Outlook Therapeutics (OTLK) targets $50M-$75M first-year US revenue for newly approved LYTENAVA

quartrimportance 0.60trust 0.60Outlook Therapeutics, Inc. +0.60LYTENAVA +0.60Food and Drug Administration +0.50

2026-08-14 11:41:30 UTC#177649duplicateconfirmednews

Outlook Therapeutics (OTLK) reports narrowed Q3 loss, confirms LYTENAVA US launch by end of 2026

quartrimportance 0.40trust 0.70Outlook Therapeutics, Inc. +0.60LYTENAVA +0.70Food and Drug Administration +0.50

2026-08-14 11:26:13 UTC#177583newconfirmednews

Outlook Therapeutics Q3 net loss narrows on lower expenses; plans US LYTENAVA launch by end of 2026

reutersimportance 0.40trust 0.80Outlook Therapeutics, Inc. +0.20LYTENAVA +0.40U.S. Food and Drug Administration 0

2026-08-14 11:18:05 UTC#177533updateconfirmednews

Outlook Therapeutics Q3 2026 Non-GAAP EPS -$0.09 misses by $0.02, Revenue $0.01M misses by $0.96M

seeking alphaimportance 0.40trust 0.80Outlook Therapeutics, Inc. -0.40

2026-08-14 11:15:00 UTC#177490newconfirmeddata release

Outlook Therapeutics reports Q3 2026 loss of $0.15 per share

dow_jonesimportance 0.40trust 0.90Outlook Therapeutics, Inc. -0.30

2026-08-13 18:43:46 UTC#173752newforecastnews

Outlook Therapeutics Q3 2026 Earnings Preview

seeking alphaimportance 0.30trust 0.60Outlook Therapeutics, Inc. 0

2026-08-13 08:17:30 UTC#170209duplicateconfirmednews

Outlook Therapeutics shares decline following pricing of $55M public securities offering

seeking alphaimportance 0.30trust 0.70Outlook Therapeutics, Inc. -0.50

2026-08-13 02:10:00 UTC#168948updateconfirmednews

Outlook Therapeutics grants underwriters option to purchase up to 8.3M additional shares and warrants

dow_jonesimportance 0.40trust 0.90Outlook Therapeutics, Inc. -0.20

2026-08-13 02:10:00 UTC#168947updateconfirmednews

Outlook Therapeutics prices public offering at $0.99 per share and warrant unit

dow_jonesimportance 0.40trust 0.90Outlook Therapeutics, Inc. -0.40

2026-08-13 02:10:00 UTC#168946duplicateconfirmednews

Outlook Therapeutics Prices 55.6M Share Public Offering with Accompanying Warrants

dow_jonesimportance 0.30trust 0.90Outlook Therapeutics, Inc. -0.40

2026-08-13 02:10:00 UTC#168945updateconfirmednews

Outlook Therapeutics to use $55M offering proceeds to support US commercial launch of LYTENAVA

dow_jonesimportance 0.40trust 0.80Outlook Therapeutics, Inc. +0.30LYTENAVA +0.40

2026-08-13 02:10:00 UTC#168944updateconfirmednews

Outlook Therapeutics (OTLK) expects $55M public offering to close August 14

dow_jonesimportance 0.30trust 0.90Outlook Therapeutics, Inc. 0

2026-08-13 02:10:00 UTC#168943updateconfirmednews

Outlook Therapeutics (OTLK) prices public offering for $55 million in gross proceeds

dow_jonesimportance 0.50trust 0.90Outlook Therapeutics, Inc. -0.30

2026-08-13 02:10:00 UTC#168942newconfirmednews

Outlook Therapeutics (OTLK) to allocate capital raise proceeds for working capital and general corporate purposes

dow_jonesimportance 0.30trust 0.80Outlook Therapeutics, Inc. -0.20